Alzheimer’s conference preview offering context on planned presentations and their implications for clinicians, researchers, and interested readers.
Key Takeaways
- Eisai’s upcoming conference presentations cover therapeutic targets
- Eisai will present lecanemab results showing a subcutaneous formulation and three-year real-world outcomes
- Eisai will present etalanetug pharmacodynamic data alongside a novel CSF eMTBR-tau243 immunoassay